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Objectives: A growing incidence of pathogens producing carbapenemases has been observed in many
countries including Bangladesh. The present study was carried out to determine the presence of car-
bapenemase producers among uropathogens.
Materials and Methods: A total of 138 Gram-negative uropathogens were isolated and identiﬁed by
conventional methods and were screened for carbapenemase production using imipenem discs.
Phenotypic identiﬁcation of carbapenemase production was done by the double disc synergy test,
combined disc assay, and modiﬁed Hodge test. The minimum inhibitory concentration of imipenem was
determined by the agar dilution method. Genes encoding blaNDM-1, blaIMP, blaVIM, blaKPC and blaOXA-
48/blaOXA-181 were identiﬁed by polymerase chain reaction.
Results: Twenty (14.49%) imipenem resistant strains were detected among 138 Gram-negative uro-
pathogens. The most common isolates were Escherichia coli and Klebsiella spp. Among 20 imipenem
resistant strains, 16 (80%) carbapenemase producers were detected by polymerase chain reaction, 13
(65%) by double disc synergy, 15 (75%) by combined disc assay, and seven (35%) by modiﬁed Hodge test.
The blaNDM-1 gene was most prevalent (55%), followed by blaOXA-48/OXA-181, blaKPC (20%), blaVIM
(15%), and blaIMP (10%). More than one carbapenemase gene was present in nine (45%) of the isolates.
The minimum inhibitory concentration of imipenem of the carbapenemase producers ranged from
128 mg/mL to 4 mg/mL. Overall, carbapenemase encoding genes were detected in 11.6% (16/138) of the
studied Gram-negative uropathogens. All (100%) of the carbapenemase-producing organisms were
resistant to all tested antibiotics apart from colistin.
Conclusion: The study shows a signiﬁcant rate of urinary isolates were carbapenemase producers,
including a high prevalence of blaNDM-1, in Bangladesh.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Carbapenems are the mainstay of therapy for patients with
serious and life threatening infections caused by Enter-
obacteriaceae, which produce extended spectrum b-lactamases
(ESBL) [1]. However, the widespread emergence and dissemination
of carbapenem resistance in this family has resulted in a public
health crisis [2]. This resistance is mediated by production of car-
bapenemases [either serine based carbapenemase or metallo-b-
lactamases (MBLs)], by modiﬁcation of membrane permeabilityogy, Dhaka Medical College,
8615919.
(N. Begum).
lief Tzu Chi Foundation. Published(i.e., porin loss) or by production of carbapenem hydrolyzing b-
lactamases (i.e., hyperproduction of AmpC b-lactamase, certain
ESBLs with increased capacity to hydrolyze carbapenems) and
upregulation of efﬂux pumps [3]. Carbapenem-hydrolyzing b-lac-
tamases, which belong to Ambler classes A, B, and D have been
reported worldwide among Enterobacteriaceae. The most clinically
signiﬁcant ones are KPC-type (class A); IMP, VIM, and NDM-1 types
(class B); and OXA-48 (class D). The genes encoding them are
located on mobile genetic elements, which allow them to spread
[1,4]. Class A and D enzymes have a serine-based hydrolytic
mechanism for cleaving the b-lactam ring in antibiotics. MBLs, by
contrast, are class B carbapenemases containing zinc at the active
site [5]. Carbapenemase-producing pathogens are considered a
serious nuisance as they have the ability to hydrolyze penicillins,
cephalosporins, and monobactams as well as carbapenems [6].by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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otics, the pathogens remain susceptible only to colistin and tige-
cycline combination therapy [7]. However, with its increased use,
we may actually trigger resistant mechanisms against these com-
binations leading to the end of the current era of pharmacopoeia
[8]. The objective of our study was to isolate and study the occur-
rence of blaNDM-1 and other carbapenemase genes among urinary
isolates in Bangladesh, along with the antimicrobial resistance
patterns of these organisms. This knowledge will greatly help
reduce the morbidity and mortality rates associated with urinary
tract infections caused by these organisms.
2. Materials and methods
2.1. Bacterial isolates
The study was conducted after obtaining due approval from the
institutional ethical committee. From January to December 2014, a
total of 138 consecutive nonduplicate (one isolate per patient)
Gram-negative isolates recovered from urine cultures of patients
with clinically suspected urinary tract infection in the Department
of Microbiology of Dhaka Medical College, Dhaka were included in
the study. Bacterial identiﬁcation was performed by routine con-
ventional microbial cultures and biochemical tests using standard
recommended techniques [9].
2.2. Antimicrobial susceptibility testing
All bacterial isolates were subjected to antimicrobial suscepti-
bility testing using the disc diffusion method as described by the
Clinical and Laboratory Standards Institute (CLSI) [10]. Escherichia
coli ATCC 25922 was used as the quality control strain. The anti-
biotics tested were as follows (potency in mg/disc): ceftazidime
(30), ceftriaxone (30), imipenem (10), meropenem (10), cefotaxime
(30), cefoxitin (30), amoxiclav (20/10), ciproﬂoxacin (5), gentamicin
(10), co-trimoxazole (1.25/23.75), azithromycin (15), nitrofurantoin
(300), and colistin sulfate (10).
2.3. Screening for carbapenemases by the disc diffusion technique
Screening for carbapenem-resistance was determined using the
KirbyeBauer disc diffusion method with a 10 mg imipenem disc.
Three to ﬁve well isolated colonies of test organisms were emul-
siﬁed into 3 mL of sterile normal saline. The turbidity of the
suspension was compared with the 0.5 McFarland turbidity stan-
dard and the suspension was incubated on MuellereHinton agar
plates at 37C for 24 hours. An inhibition zone of 19mmdiameter
around the imipenem disc was considered resistant, 20e22 mm
indicated intermediate, and 23 mm was considered sensitive
[10].
2.4. Phenotypic detection of carbapenemase producers
All the isolates showing reduced susceptibility to imipenem
(zone diameter ˂19mm)were tested for carbapenemase production
using the modiﬁed Hodge test. Brieﬂy, a lawn culture (0.5 McFar-
land) of E. coli 25922 was streaked on a MuellereHinton agar plate.
A 10 mg meropenem disc was placed in the center of the agar plate.
The test isolates were streaked in a straight line from the edge of
the disc to the edge of the plate and were incubated overnight. A
positive test was indicated by a cloverleaf-like indentation at the
intersection of the test organism and the standard strain, within the
zone of inhibition of the carbapenem antibiotic [10]. The detection
of MBL production was performed by the double-disc synergy(DDS) test and combined disc (CD) assay as described previously
[11,12].
2.5. Detection of carbapenemase producers by the minimum
inhibitory concentration of imipenem
The minimum inhibitory concentration (MIC) of imipenem
against all carbapenemase producers was determined using the
agar dilution method according to CLSI guidelines. For detection of
carbapenem resistance among Enterobacteriaceae, an MIC of
imipenem 4 mg/mL was considered resistant, 2 mg/mL interme-
diate, and 1 mg/mL sensitive [10]. For preparation of the imipe-
nem stock solution, a vial of a 500 mg base of commercially
available imipenem injectionwas added to 50 mL distilled water to
a concentration of 10mg/mL. For each plate, 50mLMuellereHinton
medium was prepared and impregnated with 5 mL, 10 mL, 20 mL,
40 mL, 80 mL, 160 mL, 320 mL, 640 mL, or 1280 mL of the imipenem
stock solution to achieve concentrations of 1 mg/mL, 2 mg/mL, 4 mg/
mL, 8 mg/mL, 16 mg/mL, 32 mg/mL, 64 mg/mL, 128 mg/mL, or 256 mg/
mL per plate, respectively.
2.6. Molecular characterization of carbapenem resistance genes
Polymerase chain reaction (PCR)-based detection of Ambler
class B MBLs (blaIMP, blaVIM and blaNDM-1), Ambler class D
(blaOXA-48/OXA-181), and serine carbapenemases (blaKPC) was
carried out on imipenem resistant isolates. Coexistence of carba-
penemase encoding genes, namely, NDM-1, VIM, IMP, OXA-48/
OXA-181 and KPC were also evaluated by PCR. Genomic DNA was
extracted by the boiling method. The following pairs of previously
used primers were used to yield PCR products: for blaNDM-1: ACC
GCC TGG ACC GAT GAC CA (forward), GCC AAA GTT GGG CGC GGT
TG (reverse); for blaIMP: GGA ATA GAG TGG CTT AAY TCT C (for-
ward), CCA AAC YAC TAS GTT ATC T (reverse); for blaVIM: GAT GGT
TTG GTC GCA TA (forward), CGA ATG CGC AGC ACC AG (reverse); for
blaKPC: CGT CTA GTT CTG CTG TCT TG (forward), CTT GTC ATC CTT
GTT AGG CG (reverse); for blaOXA-48: GCG TGG TTA AGG ATG AAC
AC (forward), CAT CAA GTT CAA CCC AAC CG (reverse); and for
blaOXA-181: ATG CGT GTA TTA GCC TTA TCG (forward), AAC TAC
AAG CGC ATC GAG CA (reverse) [13e16]. The following cycling
parameters were used: initial denaturation at 95C for 10 minutes,
then 30 cycles of denaturation at 95C for 1 minute, annealing at
63C (for blaNDM-1 and blaOXA-48), 52C (for blaIMP and blaVIM),
or 55C (for blaOXA-181) for 45 seconds, extension at 72C for 1
minute, and ﬁnal extension at 72C for 10 minutes. The ampliﬁed
DNA was analyzed by 1.5% agarose gel-electrophoresis at 100 volts
for 35 minutes, stained with 1% ethidium bromide and visualized
under UV light.
2.7. Statistical analysis
Data were analyzed using Excel (2007) software (Microsoft,
Redmond, WA, USA).
3. Results
Twenty of the total 138 Gram-negative urinary isolates (14.49%)
were found to be imipenem resistant by the disk diffusion test and
by the MIC of imipenem. Thirteen E. coli, ﬁve Klebsiella spp., one
Citrobacter spp. and one Pseudomonas spp. were isolated from the
imipenem-resistant organisms. The MIC of imipenem of these
isolates ranged from 128 mg/mL to 4 mg/mL. Among 20 imipenem-
resistant strains, 16 (80%) carbapenemase producers were detected
by PCR. Eleven (84.62%) of the 13 imipenem-resistant E. coli, four
(80%) of the ﬁve Klebsiella spp., and the only Citrobacter spp. were
Fig. 1. Photograph of ampliﬁed NDM-1, OXA-48, OXA-181, KPC, VIM and IMP genes.
Lane 4: 100-bp DNA ladder; Lane 2: ampliﬁed DNA of 390 bp for the VIM gene; Lane 3:
888 bp for the OXA-181 gene; Lane 5: 438 bp for the OXA-48 gene; Lane 6: 264 bp for
the NDM-1 gene; Lane 7: 188 bp for the IMP gene; Lane 8: and 498 bp for KPC gene;
Lane 1: negative control (Escherichia coli ATCC 25922).
Table 2
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imipenem resistant Pseudomonas spp. was negative for
carbapenemase-encoding genes. Out of 20 imipenem-resistant
strains, 11 (55%) were positive for blaNDM-1, 8 (40%) for blaOXA-
48/blaOXA-181, 4 (20%) for blaKPC, 3 (15%) for blaVIM, and 2 (10%)
for blaIMP (Table 1).
Representative PCR ampliﬁed NDM-1, VIM, IMP, OXA-48/OXA-
181, and KPC genes are shown in Fig. 1.
Among the carbapenemase-producing organisms, nine (45%)
contained two or more carbapenemase genes, seven (35%) con-
tained a single carbapenemase gene, and four (20%) had no car-
bapenemase gene. Among the 16 carbapenemase producers,
blaNDM-1þ blaOXA-48/OXA-181 was the predominant combina-
tion, which was present in four (25%) of the isolates (Table 2).
The DDS test, CD assay, and modiﬁed Hodge test detected 13
(65%), 15 (75%), and seven (35%) carbapenemase producers,
respectively, among the 20 imipenem-resistant isolates. Out of the
four negative ampliﬁed PCR products, three were positive by the
DDS test and all were positive by CD assay andmodiﬁed Hodge test.
Considering PCR as the gold standard, the sensitivity of the DDS
test, CD assay, and MHT test were 62.5%, 68.75%, and 18.75%,
respectively. All (100%) of the carbapenemase-producing organ-
isms showed resistance to other b-lactam antibiotics, aminoglyco-
sides and quinolones tested but were found to be sensitive to
colistin.Distribution of blaVIM, blaIMP, blaNDM-1, blaOXA-48/OXA-181, blaKPC
among imipenem-resistant organisms.
Genotype n (%)
NDMe1þOXAe48/OXAe181þ KPC 1 (5)
NDMe1þ IMPþVIM 2 (10)
NDMe1þOXAe48/OXAe181 4 (20)
NDMe1þ KPC 2 (10)
NDMe1 2 (10)
VIM 1 (5)
OXAe48/OXAe181 3 (15)
KPC 1 (5)4. Discussion
The global emergence and dissemination of acquired carbape-
nemases among Gram-negative bacteria are considered a major
public health problem. The carbapenemase-encoding genes are
often located on plasmids along with other resistance genes,
resulting in multidrug-resistant, extremely drug-resistant and
pandrug-resistant bacteria [17]. Continuous monitoring and rapid
detection of these virulent organisms may check their spread and
play a vital role in infection control. To address this rising resistant
determinant, we have observed the occurrence of carbapenemase-
encoding genes among carbapenem-resistant Gram-negative
uropathogens.
The present study identiﬁed 16 (80%) carbapenemase producers
out of the 20 imipenem-resistant bacteria, which included 84.62%
of the imipenem-resistant E. coli and 80% of the imipenem-resistant
Klebsiella spp. Although acquired carbapenemase-encoding genes
are frequently found in Pseudomonas spp. and Acinetobacter spp.,
the existence of carbapenemase-encoding genes in the species of
E. coli and Klebsiella pneumoniae in this study suggests that
plasmid-mediated horizontal transfer of carbapenemase-encoding
genes occurs continuously among Gram-negative bacilli, as re-
ported previously [2].
In the present study, out of 20 imipenem-resistant Gram-
negative bacteria, 11 (55%) blaNDM-1 producers were detected by
PCR, including seven (53.85%) of the imipenem-resistant E. coli andTable 1
Distribution of carbapenemase-encoding genes among different species of imipenem re
Imipenem-resistant organisms
NDM-1 (%) VIM (%)
Escherichia coli (n¼ 13) 7 (53.85) 2 (15.38)
Klebsiella spp. (n¼ 5) 4 (80.00) 1 (20.00)
Citrobacter spp. (n¼ 1) 0 (0.00) 0 (0.00)
Pseudomonas spp. (n¼ 1) 0 (0.00) 0 (0.00)
Total (n¼ 20) 11 (55.00) 3 (15.00)
The total of last row is more than 100% as most of the isolates had two or more carbapefour (80%) of the imipenem-resistant Klebsiella spp. The prevalence
of blaNDM-1 producers is increasing in Bangladesh, which is re-
ﬂected by several studies conducted in Bangladesh [18,19]. In In-
dian studies, the prevalence of blaNDM-1 producers among
carbapenem-resistant Enterobacteriaceae ranged between 31.2%
and 91.6% [20]. An editorial by Abdul Ghafur highlights the wide-
spread nonprescription use of antibiotics in this subcontinent,
leading to huge selection pressure, and predicts that the NDM-1
problem is likely to get substantially worse in the foreseeable
future [21]. This scenario is of great concern because there are few
new antieGram-negative antibiotics in the pharmaceutical pipe-
line and none that are active against NDM-1 producers [7]. A study
by Bushnell et al reported that urine was the most common spec-
imen source and K. pneumoniae and E. coliwere themost frequently
detected bacteria detected in 60 cases of blaNDM-1 producing
bacteria [22]. Rapid dissemination of blaNDM-1 producingsistant organisms.
Carbapenemase-encoding genes
IMP (%) OXA-48/OXA-181 (%) KPC (%)
2 (15.38) 5 (38.46) 3 (23.08)
0 (0.00) 2 (40.00) 1 (20.00)
0 (0.00) 1 (100.00) 0 (0.00)
0 (0.00) 0 (0.00) 0 (0.00)
2 (10.00) 8 (40.00) 4 (20.00)
nemase genes.
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over-the-counter availability of antibiotics, low levels of hygiene,
and weak hospital antibiotic policies [23].
Among 20 imipenem-resistant isolates, four (20%) were positive
for the blaKPC gene. So far there are no reports of blaKPC positive
Enterobacteriaceae in Bangladesh. In the current study, three
(23.08%) of the imipenem-resistant E. coli and one (20%) of the
imipenem-resistant Klebsiella spp. were positive for the blaKPC
gene. The highest prevalence of KPC producing organisms to date
were identiﬁed mostly in the USA, Israel, and Greece [24]. Shan-
mugam et al in India reported that 31 (67.4%) of 46 carbapenem-
resistant Enterobacteriaceae isolates harbored the blaKPC gene
[25]. The blaKPC genes that encode KPCs are present on transfer-
able plasmids and are ﬂanked by transposable elements, thus
allowing for the gene to move from plasmid to the bacterial chro-
mosome and back [26]. The presence of this gene suggests the
possibility of horizontal transmission, as this carbapenemase has
been associated with mobile genetic elements (transposons),
which can be transferred from one bacterium to another [27].
A point mutant analog of OXA-48, OXA-181, with similar car-
bapenemase activity, has been identiﬁed in strains from India and
strains of Indian origin [16]. In the current study, out of 20
imipenem-resistant Gram-negative isolates, 8 (40%) were positive
for blaOXA-181 and OXA-48 detected by PCR (using speciﬁc
primer). These included ﬁve (38.46%) of the imipenem-resistant
E. coli, two (40%) of the imipenem-resistant Klebsiella spp., and
the one (100%) imipenem-resistant Citrobacter spp. PCR screening
results need to be validated by sequencing to ascertain the presence
of either OXA-48 or OXA-181, which was not performed in the
present study, although OXA-181 is more common in the Indian
subcontinent than OXA-48. In September 2012, the CDC reported
isolation of blaOXA-181 positive K. pneumoniae in two patients
from Bangladesh who were admitted to separate hospitals in
Singapore within a short period [28]. A study by Castanheira et al in
India reported that 10 of 39 (25.64%) carbapenem-resistant strains
harbored the blaOXA-181 gene [16]. The ﬁndings in the present
study revealed that blaOXA-48/OXA-181 carbapenemase-
producing organisms appear to be an emerging cause of carbape-
nem resistance in Gram-negative bacteria in Bangladesh in addi-
tion to blaNDM-1-producing organisms.
Combinations of different genes in single strains were observed,
with a combination of blaNDM-1 and blaOXA-48/blaOXA-181 being
predominant (20%). A study by Khajuria et al in India reported 55%
of carbapenemase-producing urinary isolates of E. coli co-harbored
blaNDM-1 and blaOXA-48 [29]. Plasmids carrying the blaNDM-1
gene are diverse and can harbor a high number of resistance genes
associated with other carbapenemase genes (OXA-48 types, VIM
types), plasmid-mediated cephalosporinase genes, ESBL genes,
aminoglycoside resistance genes (16S RNA methylases), macrolide
resistance genes (esterase), and rifampin (rifampin-modifying en-
zymes) and sulfamethoxazole resistance genes as sources of
multidrug resistance and pandrug resistance [20].
The actual prevalence of carbapenemase producers among
Gram-negative bacteria is still unknown because many countries
that are likely to be their main reservoirs have not established any
search protocol for their detection [30]. In the present study, 16.2%
(16/138) of Gram-negative uropathogens showed the occurrence of
carbapenemase encoding genes, which is almost four times higher
than other data reported in Bangladesh, where only 4.8% isolates
were found to be carbapenemase producers [31]. The discrepancy
in the ﬁndings between the latter and present studies might be due
the increased use of carbapenem in Dhaka, Bangladesh.
Imipenem discs were used for screening carbapenemase pro-
duction. However, we observed that four (20%) imipenem-resistant
strains showed negative ampliﬁcation by PCR. Gram-negativebacteria have the capacity to elude the action of carbapenems
through modiﬁcation of outer membrane permeability (i.e. porin
loss), upregulation of efﬂux systems, production of carbapenem-
hydrolyzing b-lactamases (i.e. hyperproduction of AmpC b-lacta-
mases, certain ESBLs with increased capacity to hydrolyze carba-
penems) and production of carbapenemases (either serine based
carbapenemases or MBLs) [3]. The plethora of imipenem resistance
among the noncarbapenemase producers in this study might be
due to resistance mechanisms other than carbapenemase
production.
In addition to showing resistance to b-lactams, all the
carbapenemase-producing organismswere highly resistant tomost
other antibiotic classes, including aminoglycosides and ﬂuo-
roquinolones. The higher antibiotic resistance in the present study
might be due to the fact that common antibiotics are sold over the
counter in Bangladesh and anybody can buy them without a doc-
tor's advice. By contrast, the coresistance of MBL producers to non-
b-lactam antibiotics might be due to simultaneous presence of
other drug resistance mechanisms in addition to MBL genes [32].
5. Conclusion
This study shows a signiﬁcant rate of carbapenemase producing
Gram-negative uropathogens. This is extremely worrisome, as
dissemination of plasmids carrying resistant determinant genes
from one species to another makes organisms refractory to the
common antibiotics used in clinical practice. The need of the hour is
a strong antimicrobial stewardship program, which is followed by
all concerned doctors, with further emphasis on better, cost-
effective, logical infection control measures to prevent the
dissemination of these multidrug resistant bacteria.
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